Mutation-Agnostic Detection of Colorectal Cancer Using Liquid Biopsy-Based Methylation-Specific Signatures
The Oncologist · 2023
DOI: 10.1093/oncolo/oyac204 ↗Kurz gefasst
Fachartikel in der Zeitschrift The Oncologist, 2023. Verfasst von Mohamed A Gouda und 15 weiteren Autor:innen. Beteiligte Einrichtung: Department of Translational Molecular Pathology, The University of Texas MD Anderson Cancer Center, Houston, USA. Hauptthemen laut MEDLINE: Neoplasms, Circulating Tumor DNA, Colorectal Neoplasms. Die Arbeit wurde bisher 10-mal zitiert (Crossref) und nennt 20 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC 4.0). Gefördert von: Rising Tide Foundation.
Abstract (Originalsprache)
Detection of methylation patterns in circulating tumor DNA (ctDNA) can offer a novel approach for cancer diagnostics given the unique signature for each tumor type. We developed a next-generation sequencing (NGS)-based assay targeting 32 CpG sites to detect colorectal cancer-specific ctDNA. NGS was performed on bisulfite-converted libraries and status dichotomization was done using median methylation ratios at all targets. We included plasma samples from patients with metastatic colorectal (n = 20) and non-colorectal cancers (n = 8); and healthy volunteers (n = 4). Median methylation ratio was higher in colorectal cancer compared with non-colorectal cancers (P = .001) and normal donors (P = .005). The assay detected ctDNA in 85% of patients with colorectal cancer at a specificity of 92%. Notably, we were able to detect methylated ctDNA in 75% of patients in whom ctDNA was not detected by other methods. Detection of methylated ctDNA was associated with shorter median progression-free survival compared to non-detection (8 weeks versus 54 weeks; P = .027).
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Translational Molecular Pathology, The University of Texas MD Anderson Cancer Center, Houston, USA.
- Department of Investigational Cancer Therapeutics, The University of Texas MD Anderson Cancer Center, Houston, USA.
- Department of Clinical Oncology and Nuclear Medicine, Faculty of Medicine, Menoufia University, Shebin Al-Kom, Egypt.
- Department of Hematology and Oncology, Stavanger University Hospital, Stavanger, Norway.
- Department of Bioinformatics and Computational Biology, The University of Texas MD Anderson Cancer Center, Houston, USA.
- Department of Gastrointestinal Medical Oncology, The University of Texas MD Anderson Cancer Center, Houston, USA.
ORCID-Profile: Mohamed A Gouda, Scott Kopetz
Förderung
- Rising Tide Foundation
Zitieren
APA
Gouda, M. A., Duose, D. Y., Lapin, M., Zalles, S., Huang, H. J., Xi, Y., Zheng, X., Aldesoky, A. I., Alhanafy, A. M., Shehata, M. A., Wang, J., Kopetz, S., Meric-Bernstam, F., Wistuba, I. I., Luthra, R., & Janku, F. (2023). Mutation-Agnostic Detection of Colorectal Cancer Using Liquid Biopsy-Based Methylation-Specific Signatures. The Oncologist. https://doi.org/10.1093/oncolo/oyac204
Vancouver
Gouda MA, Duose DY, Lapin M, Zalles S, Huang HJ, Xi Y, et al. Mutation-Agnostic Detection of Colorectal Cancer Using Liquid Biopsy-Based Methylation-Specific Signatures. The Oncologist. 2023. doi:10.1093/oncolo/oyac204
BibTeX
@article{Gouda2023,
author = {Gouda, Mohamed A and Duose, Dzifa Y and Lapin, Morten and Zalles, Stephanie and Huang, Helen J and Xi, Yuanxin and Zheng, Xiaofeng and Aldesoky, Amira I and Alhanafy, Alshimaa M and Shehata, Mohamed A and Wang, Jing and Kopetz, Scott and Meric-Bernstam, Funda and Wistuba, Ignacio I and Luthra, Rajyalakshmi and Janku, Filip},
title = {Mutation-Agnostic Detection of Colorectal Cancer Using Liquid Biopsy-Based Methylation-Specific Signatures},
journal = {The Oncologist},
year = {2023},
doi = {10.1093/oncolo/oyac204}
}
EUVIMED